• Issues
    • Current Issue
    • Special Issues
  • Viewpoints
    • Editor’s Corner
    • Advanced Practice Voices
    • From Our Readers
      • You Make the Call: Readers’ Response
      • Guest Commentary
      • Letters to the Editor
    • A Day in the Life
    • Notes From the Hill
    • The Break Room
  • Education
    • You Make the Call
    • Hematologica Obscura
    • How I Teach
    • How I Treat In Brief
    • Demystifying the Lab
    • Practice Update
  • Spotlight
    • Feature Articles
    • Pulling Back the Curtain
    • Blood Beyond Borders
    • pASHions
    • Drawing First Blood
    • HemOnc Link
    • Interviews
  • News
    • Online Exclusives
    • Latest & Greatest
    • From the Blood Journals
      • Written in Blood
      • Blood Advances in a Different Vein
    • Literature Scan
    • ASH Directions
    • The Society Pages
  • Topic Compilations
    • COVID-19 News
    • Acute Leukemias
    • Chronic Leukemias
    • MDS & Myeloproliferative Neoplasms
    • Multiple Myeloma & Plasma Cell Disorders
    • Lymphomas & Lymphoid Neoplasia
    • Bleeding Disorders
    • Clotting Disorders
    • Red Blood Cell & Iron Disorders
  • On Location
    • ASH Annual Meeting
    • ASH Meeting on Hematologic Malignancies
    • ASH Meeting on Lymphoma Biology
    • Other Meetings
  • Multimedia
    • Sound Bites
    • Meeting Coverage
Search
  • ASH Home
  • About ASH Clinical News
  • Authors
  • Advertising
  • Subscribe
  • Contact Us
  • eNewsletters
  • Cookie Settings
  • LOG IN
Welcome! Log into your account
Forgot your password?
Recover your password
ASH Clinical News
  • Issues
    • AllCurrent IssueSpecial Issues

      April 2021 Volume 7 Issue 5

      March 2021 Special Edition

      March 2021 Volume 7 Issue 4

      February 2021 Volume 7 Issue 3

  • Viewpoints
    • Editor’s Corner
    • Advanced Practice Voices
    • From Our Readers
      • You Make the Call: Readers’ Response
      • Guest Commentary
      • Letters to the Editor
    • A Day in the Life
    • Notes From the Hill
    • The Break Room
  • Education
    • You Make the Call
    • Hematologica Obscura
    • How I Teach
    • How I Treat In Brief
    • Demystifying the Lab
    • Practice Update
  • Spotlight
    • Feature Articles
    • Pulling Back the Curtain
    • Blood Beyond Borders
    • pASHions
    • Drawing First Blood
    • HemOnc Link
    • Interviews
  • News
    • Online Exclusives
    • Latest & Greatest
    • From the Blood Journals
      • Written in Blood
      • Blood Advances in a Different Vein
    • Literature Scan
    • ASH Directions
    • The Society Pages
  • Topic Compilations
    • COVID-19 News
    • Acute Leukemias
    • Chronic Leukemias
    • MDS & Myeloproliferative Neoplasms
    • Multiple Myeloma & Plasma Cell Disorders
    • Lymphomas & Lymphoid Neoplasia
    • Bleeding Disorders
    • Clotting Disorders
    • Red Blood Cell & Iron Disorders
  • On Location
    • ASH Annual Meeting
    • ASH Meeting on Hematologic Malignancies
    • ASH Meeting on Lymphoma Biology
    • Other Meetings
  • Multimedia
    • Sound Bites
    • Meeting Coverage
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Home MDS & Myeloproliferative Neoplasms
  • MDS & Myeloproliferative Neoplasms
  • Meeting Coverage
  • Multimedia
  • Non-ASH Meetings

Naveen Pemmaraju: A New Option for Myelofibrosis?

Sunday, June 2, 2019

Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.

SHARE
ajones
Advertisement

Recent Articles

New Children’s Hospital Coalition Aims to Combat Pandemic-Driven Drug Shortages

Thursday, April 15, 2021
Eleven children’s hospitals have teamed up to form The Children’s Hospital Coalition, aimed at mitigating the effects of drug shortages caused by the COVID-19...

Study Finds Children with Down Syndrome Have Higher Risk of AML

Thursday, April 15, 2021
Children with Down syndrome have an estimated 150-fold higher risk of developing acute myeloid leukemia (AML) before age five, compared to children without Down...

Biden Administration Proposes $6.5 Billion Health Research Agency

Thursday, April 15, 2021
The U.S. federal government has proposed dedicating $6.5 billion to establish a medical research agency focused on curing cancer, Alzheimer’s, diabetes, and other diseases. If...

European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma

Sunday, April 11, 2021
Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...

FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma

Sunday, April 11, 2021
Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the...

Current Issue

April 2021 Volume 7 Issue 5

Thursday, April 1, 2021
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.
Related Articles
Recent Posts
  • New Children’s Hospital Coalition Aims to Combat Pandemic-Driven Drug Shortages
  • Study Finds Children with Down Syndrome Have Higher Risk of AML
  • Biden Administration Proposes $6.5 Billion Health Research Agency
  • European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma

Meeting Coverage

Researchers Validate Burkitt Lymphoma Prognostic Index

Monday, March 1, 2021

Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL

Monday, March 1, 2021

Editor's Corner

Editor’s Corner: Post-Pandemia Mania

Thursday, April 1, 2021

Editor’s Corner: Healing Our Invisible Wounds

Monday, March 1, 2021
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
  • ASH Home
  • Research
  • Education
  • Advocacy
  • Meetings
  • Publications
  • ASH Store
Copyright © 2020 by American Society of Hematology

Contact Us | Terms of Service | Privacy Policy